Transdermal rotigotine in advanced Parkinson’s disease: A randomized, double-blind, placebo-controlled trial

Journal of Neurology

Volumn 261, Issue 10, 2014, Pages 1887-1893

  Nomoto, Masahiro ^a   Mizuno, Yoshikuni ^b   Kondo, Tomoyoshi ^b   Hasegawa, Kazuko ^c   Murata, Miho ^d   Takeuchi, Masahiro ^e   Ikeda, Junji ^f   Tomida, Takayuki ^f   Hattori, Nobutaka ^b  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c SAGAMIHARA NATIONAL HOSPITAL   (Japan)

^d National Center Hospital for Neurology and Psychiatry   (Japan)

^e KITASATO UNIVERSITY   (Japan)

^f OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Advanced Parkinson s disease; Dyskinesia; Randomized controlled trial; Rotigotine; Wearing off

Indexed keywords

CREATINE KINASE; LEVODOPA; ROTIGOTINE; DOPAMINE RECEPTOR STIMULATING AGENT; TETRALIN DERIVATIVE; THIOPHENE DERIVATIVE;

ADULT; AGED; ANEMIA; ANOREXIA; APPLICATION SITE ERYTHEMA; APPLICATION SITE PRURITUS; APPLICATION SITE REACTION; ARTICLE; AUDITORY HALLUCINATION; CONSTIPATION; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DELUSION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; FALLING; FEMALE; HEADACHE; HOEHN AND YAHR SCALE; HUMAN; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALAISE; MALE; NAUSEA AND VOMITING; NEUROLEPTIC MALIGNANT SYNDROME; ON OFF PHENOMENON; OUTCOME ASSESSMENT; PARKINSON DISEASE; POSITIONAL DIZZINESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SKIN BRUISING; SOMNOLENCE; TRANSDERMAL PATCH; UNIFIED PARKINSON DISEASE RATING SCALE; VISUAL HALLUCINATION; INTRADERMAL DRUG ADMINISTRATION; MIDDLE AGED; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; DOPAMINE AGONISTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TETRAHYDRONAPHTHALENES; THIOPHENES; TREATMENT OUTCOME;

EID: 84914132867     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-014-7427-3     Document Type: Article

References (22)

1. Cotzias GC, Van Woert MH, Schiffer LM (1967) Aromatic amino acids and modification of parkinsonism. New Engl J Med 276: 374-379.
2. Lang AE, Lozano AM (1998) Parkinson's disease. First of two parts. New Engl J Med 339: 1044-1053.
3. Marsden CD, Parkes JD (1976) "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet 1: 292-296.
4. Ahlskog JE, Muenter MD (2001) Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 16: 448-458.
5. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 342: 1484-1491.
6. Parkinson Study Group (2000) Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 284: 1931-1938.
7. Parkinson Study Group (2004) Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 61: 1044-1053.
8. Oertel WH, Wolters E, Sampaio C, Gimenez-Roldan S, Bergamasco B, Dujardin M et al (2006) Pergolide versus levodopa monotherapy in early Parkinson's disease patients: the PELMOPET study. Mov Disord 21: 343-353.
9. Baronti F, Mouradian MM, Davis TL, Giuffra M, Brughitta G, Conant KE et al (1992) Continuous lisuride effects on central dopaminergic mechanisms in Parkinson's disease. Ann Neurol 32: 776-781.
10. Engber TM, Susel Z, Juncos JL, Chase TN (1989) Continuous and intermittent levodopa differentially affect rotation induced by D-1 and D-2 dopamine agonists. Eur J Pharmacol 168: 291-298.
11. Nutt JG, Obeso JA, Stocchi F (2000) Continuous dopaminereceptor stimulation in advanced Parkinson's disease. Trends Neurosci 23(Suppl): 109-115.
12. Olanow CW, Obeso JA, Stocchi F (2006) Continuous dopaminereceptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 5: 677-687.
13. Scheller D, Ullmer C, Berkels R, Gwarek M, Lübbert H (2009) The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease. Naunyn-Schmiedebergs Arch Pharmacol 379: 73-86.
14. Boroojerdi B, Wolff HM, Braun M, Scheller DKA (2010) Rotigotine transdermal patch for the treatment of Parkinson's disease and restless legs syndrome. Drugs Today 46: 483-505.
15. Pfeiffer RF (2002) Potential of transdermal drug delivery in Parkinson's disease. Drugs Aging 19: 561-570.
16. Cawello W, Braun M, Boekens H (2009) Absorption, disposition, metabolic fate, and elimination of the dopamine agonist rotigotine in man: administration by intravenous infusion or transdermal delivery. Drug Metab Dispos 37: 2055-2060.
17. Malik M, Andreas JO, Hnatkova K, Hoeckendorff J, Cawello W, Middle M et al (2008) Thorough QT/QTc study in patients with advanced Parkinson's disease: cardiac safety of rotigotine. Clin Pharmacol Ther 84: 595-603.
18. Elshoff JP, Braun M, Andreas JO, Middle M, Cawello W (2012) Steady-state plasma concentration profile of transdermal rotigotine: an integrated analysis of three, open-label, randomized, phase I multiple dose studies. Clin Ther 34: 966-978.
19. Poewe WH, Rascol O, Quinn N, Tolosa E, Oertel WH, Martignoni E et al (2007) Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 6: 513-520.
20. LeWitt PA, Lyons KE, Pahwa R (2007) Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology 68: 1262-1267.
21. Pagano M, Gauvreau K (2000) Principles of biostatistics, 2nd edn. Duxbury Press, Belmont.
22. Food and Drug Administration, HHS (2005) International conference on harmonisation; guidance on E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs; availability. Notice. Fed Regist 70: 61134-61135.